Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $2.8 million.

  • Beam Therapeutics' Treasury Shares fell 1342.77% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 1342.77%. This contributed to the annual value of $2.6 million for FY2024, which is 1196.72% down from last year.
  • Latest data reveals that Beam Therapeutics reported Treasury Shares of $2.8 million as of Q3 2025, which was down 1342.77% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Treasury Shares registered a high of $3.4 million during Q1 2024, and its lowest value of $1.1 million during Q4 2021.
  • Moreover, its 5-year median value for Treasury Shares was $2.2 million (2023), whereas its average is $2.2 million.
  • In the last 5 years, Beam Therapeutics' Treasury Shares tumbled by 3879.41% in 2021 and then skyrocketed by 7291.58% in 2023.
  • Quarter analysis of 5 years shows Beam Therapeutics' Treasury Shares stood at $1.1 million in 2021, then skyrocketed by 50.31% to $1.7 million in 2022, then soared by 72.92% to $2.9 million in 2023, then fell by 11.97% to $2.6 million in 2024, then grew by 7.96% to $2.8 million in 2025.
  • Its Treasury Shares stands at $2.8 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.1 million for Q1 2025.